Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
atopic dermatitis
Biotech
Connect uncouples from Pfizer by scrapping eczema pact
Connect licensed the oral, peripherally acting H3R antagonist in 2012 from Arena, a company that Pfizer bought for $6.7 billion a decade later.
Nick Paul Taylor
Apr 17, 2024 6:38am
Lilly's lebrikizumab clears eczema in people with skin of color
Mar 11, 2024 9:24am
Rapt faces clinical hold after liver failure in immunology trial
Feb 20, 2024 10:42am
Itch treater Cara cuts 50% of team to extend runway into 2026
Jan 22, 2024 9:44am
Allakos drops lead asset after midphase flops, halves headcount
Jan 16, 2024 9:26am
Aclaris claims ph. 2 win for JAK inhibitor but investors spooked
Jan 10, 2024 8:35am